| 1 |
34497279 | Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. | 2021 Sep 8 |
1 |
| 2 |
31124411 | Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients. | 2019 May |
1 |
| 3 |
26684581 | Novel No-Wash Luminogenic Probes for the Detection of Transporter Uptake Activity. | 2016 Jan 20 |
1 |
| 4 |
24950369 | CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. | 2014 Sep |
1 |
| 5 |
24997317 | Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. | 2014 Nov |
3 |
| 6 |
25151207 | Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study. | 2014 Dec |
1 |
| 7 |
23381882 | Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. | 2013 Jun |
1 |
| 8 |
23440887 | Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. | 2013 Sep |
3 |
| 9 |
23503447 | Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. | 2013 Apr |
1 |
| 10 |
22174437 | Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. | 2012 Nov |
2 |